We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

L-carnitine for Fatigue in COPD (LC4COPD)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03008356
Recruitment Status : Completed
First Posted : January 2, 2017
Last Update Posted : January 23, 2019
Information provided by (Responsible Party):
Roberto P. Benzo, Mayo Clinic

Brief Summary:

supplementation with L-carnitine that is available both as an FDA-approved therapy for primary carnitine deficiency, as well as widely available as an over-the-counter ergogenic aid will improve wellbeing and function measured by questionnaires in patient with chronic obstructive pulmonary disease (COPD).

based on our review of literature that addition of health coaching (HC) to L-carnitine will yield greater gains.

Condition or disease Intervention/treatment Phase
Copd Fatigue Dietary Supplement: L-carnitine 1000 mg twice daily Behavioral: Weekly health coaching calls Dietary Supplement: Placebo capsules Phase 2 Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 33 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: L-Carnitine Supplementation With and Without Health Coaching for Fatigue in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Study Start Date : January 2017
Actual Primary Completion Date : February 2018
Actual Study Completion Date : February 2018

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Fatigue

Arm Intervention/treatment
Experimental: L-carnitine
Oral L-carnitine 1000mg twice daily
Dietary Supplement: L-carnitine 1000 mg twice daily
Oral L-carnitine to be taken twice daily for 8 weeks

Experimental: L-carnitine + health coaching
Oral L-carnitine 1000mg twice daily and weekly 10-15 minute health coaching calls
Dietary Supplement: L-carnitine 1000 mg twice daily
Oral L-carnitine to be taken twice daily for 8 weeks

Behavioral: Weekly health coaching calls
Weekly health coaching calls lasting 10-15 minutes

Placebo Comparator: Placebo
Placebo capsules twice daily
Dietary Supplement: Placebo capsules

Primary Outcome Measures :
  1. Change in Exercise Capacity as Measured by the Six Minute Walk Test (6MWT) [ Time Frame: baseline, end of 8 week intervention ]
    The 6MWT is a widely studied, standardized and widely utilized test that evaluates the global and integrated responses of all the systems involved during exercise, including the pulmonary and cardiovascular systems, systemic circulation, peripheral circulation, blood, neuromuscular units, and muscle metabolism. The self-paced 6MWT assesses the submaximal level of functional capacity. Most patients do not achieve maximal exercise capacity during the 6MWT; instead, they choose their own intensity of exercise and are allowed to stop and rest during the test.

Secondary Outcome Measures :
  1. Change in Health-Related Quality of Life as Measured by the Chronic Respiratory Questionnaire (CRQ) [ Time Frame: baseline, end of 8 week intervention ]
    The CRQ is a widely utilized and validated interviewer-administered questionnaire measuring both physical and emotional aspects of chronic respiratory disease. There are 20 questions, with each item graded on 7-point Likert scale. Scores can range from 20 to 100. Higher scores indicate better quality of life.

  2. Change in Physical Fatigue as Measured by the Chalder Fatigue Questionnaire (CFQ-11) [ Time Frame: baseline, end of 8 week intervention ]
    The CFQ-11 is a well-known, widely utilized and validated self-administered questionnaire for measuring the extent and severity of fatigue. The scoring incorporates two self-assessment scales measuring components indicative of physical fatigue [8 items] and mental fatigue [5 items]. The 11 individual items are scored from 0 (better than usual) to 3 (much worse than usual); total score range: 0-33.

  3. Physical Activity as Measured by the SenseWear Armband [ Time Frame: end of 8 week intervention ]
    The SenseWear Armband system (Temple Healthcare) is a versatile arm-band monitor allowing convenient and accurate collection of raw data regarding energy expenditure, sleep duration and quality, physical activity and movement in subjects in a free-living environment, allowing them to go about their normal daily activities. Patients will be shown how to wear the activity monitor and be asked to use it for at least 5 days for 23 hours a day. They will be provided instructions and pre-paid shipping materials for wear and return of the monitor.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion criteria:

- COPD patients with a positive screen for fatigue

Exclusion criteria:

  • Vulnerable population - pregnant women, prisoners, unable to provide consent
  • Pre-menopausal/breastfeeding women (pregnancy category B)
  • Thyroid disease
  • Anticoagulation therapy
  • Decompensated cardiac disease
  • Chronic Kidney Disease (CKD4 or above)
  • Known seizure disorder
  • Active malignancy
  • Exacerbation of underlying pulmonary disease or acute illness in the 6 weeks before screening
  • Enrollment in the past 6 weeks or currently in a cardiac or pulmonary rehab program or other physical fitness class(es).
  • Difficulty with swallowing pills

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03008356

Layout table for location information
United States, Minnesota
Mayo Clinic in Rochester
Rochester, Minnesota, United States, 55905
Sponsors and Collaborators
Mayo Clinic
Layout table for investigator information
Principal Investigator: Roberto P Benzo Mayo Clinic
Layout table for additonal information
Responsible Party: Roberto P. Benzo, PI, Mayo Clinic
ClinicalTrials.gov Identifier: NCT03008356    
Other Study ID Numbers: 16-005732
First Posted: January 2, 2017    Key Record Dates
Last Update Posted: January 23, 2019
Last Verified: January 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Additional relevant MeSH terms:
Layout table for MeSH terms